Humanized neuraminidase antibody and methods of use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/42
A61K-039/00
출원번호
US-0121235
(2009-09-28)
등록번호
US-8734803
(2014-05-27)
국제출원번호
PCT/US2009/058640
(2009-09-28)
§371/§102 date
20110906
(20110906)
국제공개번호
WO2010/037046
(2010-04-01)
발명자
/ 주소
Yusibov, Vidadi
Mett, Vadim
Shoji, Yoko
출원인 / 주소
iBio Inc.
대리인 / 주소
Fish & Richardson P.C.
인용정보
피인용 횟수 :
2인용 특허 :
82
초록
Antibodies against influenza neuraminidase, compositions containing the antibodies, and methods of using the antibodies are provided herein.
대표청구항▼
1. An isolated monoclonal antibody that binds neuraminidase, wherein the antibody has the ability to inhibit neuraminidase enzyme activity, and wherein the antibody comprises the light chain variable region amino acid sequence as set forth in amino acids 1 to 127 of SEQ ID NO:5, and the heavy chain
1. An isolated monoclonal antibody that binds neuraminidase, wherein the antibody has the ability to inhibit neuraminidase enzyme activity, and wherein the antibody comprises the light chain variable region amino acid sequence as set forth in amino acids 1 to 127 of SEQ ID NO:5, and the heavy chain variable region amino acid sequence as set forth in amino acids 1 to 137 of SEQ ID NO:6. 2. An antigen-binding fragment of an antibody that binds neuraminidase and has the ability to inhibit neuraminidase enzyme activity, wherein the antigen-binding fragment comprises a light chain variable region comprising the amino acid sequence set forth in amino acids 1 to 127 of SEQ ID NO:5, and a heavy chain variable region comprising the amino acid sequence set forth in amino acids 1 to 137 of SEQ ID NO:6. 3. The antigen-binding fragment of claim 2, wherein the antigen-binding fragment is an scFv, Fv, Fab′, Fab, diabody, linear antibody, or F(ab′)2 antigen-binding fragment. 4. The antigen-binding fragment of claim 2, wherein the antigen-binding fragment is a complementarity-determining-region (CDR), a univalent fragment, or a single domain antibody. 5. The antibody of claim 1, wherein the antibody is a recombinant antibody. 6. An antibody that binds neuraminidase, wherein the antibody has the ability to inhibit neuraminidase enzyme activity, and wherein the antibody comprises the light chain amino acid sequence set forth in SEQ ID NO:9 or SEQ ID NO:10 or the light chain amino acid sequence set forth in SEQ ID NO:9 or SEQ ID NO:10 with conservative substitutions such that it is at least 95 percent identical to the amino acid sequence set forth in SEQ ID NO:9 or SEQ ID NO:10, and wherein the antibody comprises the heavy chain amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:8 or the heavy chain amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:8 with conservative substitutions such that it is at least 95 percent identical to the amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:8. 7. The antibody of claim 6, wherein the antibody comprises the light chain amino acid sequence set forth in SEQ ID NO:9 or SEQ ID NO:10, and the heavy chain amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:8. 8. The antibody of claim 6, wherein the antibody is produced in a plant. 9. The antibody of claim 6, wherein the antibody is attached to a biological agent or a diagnostic agent. 10. The antibody of claim 9, wherein the antibody is attached to an agent that cleaves a substantially inactive prodrug to release a substantially active drug. 11. The antibody of claim 10, wherein the drug is an anti-influenza agent. 12. The antibody of claim 9, wherein the antibody is attached to an anti-viral agent. 13. The antibody of claim 12, wherein the anti-viral agent is an anti-influenza agent. 14. The antibody of claim 13, wherein the antibody is attached to a diagnostic, imaging or detectable agent. 15. The antibody of claim 14, wherein the antibody is attached to an X-ray detectable compound, a radioactive ion or a nuclear magnetic spin-resonance isotope. 16. The antibody of claim 15, wherein the antibody is attached to: (a) the X-ray detectable compound bismuth (III), gold (III), lanthanum (III) or lead (II); (b) the detectable radioactive ion copper67, gallium67, gallium68, indium111, indium113, iodine123, iodine125, iodine131, mercury197, mercury203, rhenium186, rhenium188, rubidium97, rubidium103, technetium99m or yttrium90; or (c) the detectable nuclear magnetic spin-resonance isotope cobalt (II), copper (II), chromium (III), dysprosium (III), erbium (III), gadolinium (III), holmium (III), iron (II), iron (III), manganese (II), neodymium (III), nickel (II), samarium (III), terbium (III), vanadium (II) or ytterbium (III). 17. The antibody of claim 14, wherein the antibody is attached to biotin, avidin or to an enzyme that generates a colored product upon contact with a chromogenic substrate. 18. The antibody of claim 9, wherein the antibody is attached to the biological agent as a fusion protein. 19. The antibody of claim 9, wherein the antibody is attached to the biological agent via a biologically releasable bond or selectively cleavable linker. 20. A pharmaceutical composition comprising the antibody of claim 6 and a pharmaceutically acceptable carrier. 21. The composition of claim 20, wherein the composition is formulated for parenteral administration. 22. The composition of claim 20, wherein the antibody is a recombinant, plant-produced antibody. 23. The composition of claim 20, wherein the pharmaceutically acceptable composition is an encapsulated or liposomal formulation. 24. The composition of claim 20, wherein the composition further comprises a second therapeutic agent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (82)
Johnson, David A., Amphipathic aldehydes and their uses as adjuvants and immunoeffectors.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Bosslet Klaus (Marburg DEX) Hermentin Peter (Marburg DEX) Seemann Gerhard (Marburg DEX) Kuhlmann Ludwig (Florsheim am Main DEX) Steinstrasser Axel (Liederbach DEX), Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof.
Waldmann Herman (University of Cambridge ; Department of Pathology ; Immunology Div. ; Tennis Court Road Cambridge ; CB2 1QP GB3) Walsh Louise (The University of Cambridge ; Department of Pathology ;, CDR grafted humanised chimeric T-cell antibodies.
Dalie Barbara ; Le Hung V. ; Miller Kenneth ; Murgolo Nicholas J. ; Nguyen Hanh ; Tindall Stephen ; Zavodny Paul J., Cloning and exprssion of humanized monoclonal antibodies against human interluekin-4.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Bendig Mary M. (London GBX) Kettleborough Catherine A. (Herts GBX) Saldanha Jose (Middlesex GBX), Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Mizzen, Lee A.; Chu, N. Randall; Wu, Huacheng Bill, Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Turpen, Thomas H.; Garger, Stephen J.; McCulloch, Michael J.; Cameron, Terri I.; Samonek-Potter, Michelle L.; Holtz, R. Barry, Method for recovering proteins from the interstitial fluid of plant tissues.
Barbas Carlos F. (San Diego CA) Burton Dennis R. (La Jolla CA) Lerner Richard A. (La Jolla CA), Methods for producing antibody libraries using universal or randomized immunoglobulin light chains.
Johnson Kevin Stuart,GBX ; Winter Gregory Paul,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX ; Waterhouse Peter Michael,AUX, Methods for producing members of specific binding pairs.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Oceanside CA) Horwitz Arnold H. (Los Angeles CA) Better Marc (Los Angeles CA) Wall Randolph (Sherman Oaks CA) Lei Shau-Ping (Los Angeles CA) Wilcox Ga, Modular assembly of antibody genes, antibodies prepared thereby and use.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Oceanside CA) Horwitz Arnold H. (Los Angeles CA) Better Marc (Los Angeles CA) Wall Randolph (Sherman Oaks CA) Lei Shau-Ping (Los Angeles CA) Wilcox Ga, Modular assembly of antibody genes, antibodies prepared thereby and use.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Donson Jon (Davis CA) Dawson William O. (Winter Haven FL) Granthan George L. (Riverside CA) Turpen Thomas H. (Vacaville CA) Turpen Ann M. (Vacaville CA) Garger Stephen J. (Vacaville CA) Grill Laurenc, Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes.
Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
Garger, Stephen J.; Holtz, R. Barry; McCulloch, Michael J.; Turpen, Thomas H., Process for isolating and purifying proteins and peptides from plant sources.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Pedersen Jan T. (Bath GBX) Searle Stephen M. J. (Bath GBX) Rees Anthony R. (Bath GBX) Roguska Michael A. (Ashland MA) Guild Braydon C. (Concord MA), Resurfacing of rodent antibodies.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.